Design Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Design Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 9, 2026 |
| FY2024 | Dec 31, 2024 | $0 | Mar 10, 2025 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2020 | $226.0K | Mar 10, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($69.79M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($49.59M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($66.86M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($63.31M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($35.53M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($8.28M) | Mar 10, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($79.47M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($62.38M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($78.19M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($67.59M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($35.83M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($8.33M) | Mar 10, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.13M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $44.35M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $57.06M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $48.61M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $24.78M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $6.06M | Mar 10, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($54.36M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($43.11M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($58.56M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($51.32M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($29.38M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($8.67M) | Mar 10, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $193.0K | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $340.0K | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $256.0K | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $918.0K | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $1.54M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $76.0K | Mar 10, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $226.20M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $252.09M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $289.64M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $341.14M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $390.56M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $36.52M | Mar 10, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.70M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $10.00M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $11.96M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $13.83M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $8.43M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $2.48M | Mar 10, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $212.50M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $242.10M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $277.69M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | $327.31M | Mar 10, 2025 |
| FY2023 | Dec 31, 2021 | $382.13M | Mar 19, 2024 |
| FY2022 | Dec 31, 2020 | ($11.32M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | ($3.64M) | Mar 10, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($297.01M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($227.21M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($177.63M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($110.76M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($47.46M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($11.92M) | Mar 10, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.86M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $22.56M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $21.20M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $26.50M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $298.57M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $2.38M | Mar 10, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 14, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 14, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 60.40M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | 56.75M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | 56.47M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | 55.90M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | 55.44M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 15.96M | Mar 10, 2022 |